Sibel SAKARYA, Mehmet AKMAN, Ahmet AKICI, Volkan AYDIN, Ali Serdar FAK

Baseline characteristics predicting clinical outcomes and serious adverse events in middle-aged hypertensive women: a subanalysis of the SPRINT in women aged <65 years

Background/aim: The predictability of clinical outcomes in hypertension in specific patient groups, especially underrepresented populations is the key to rational treatment. This study aimed to investigate the impact of baseline characteristics of

PDF

___

1. Humphries KH, Izadnegahdar M, Sedlak T, Saw J, Johnston N et al. Sex differences in cardiovascular disease – impact on care and outcomes. Frontiers in Neuroendocrinology 2017; 46: 46-70.
2. Joyner MJ, Barnes JN, Hart EC, Wallin BG, Charkoudian N. Neural control of the circulation: how sex and age differences interact in humans. Comprehensive Physiology 2015; 5 (1): 193- 215.
3. Abramson BL, Melvin RG. Cardiovascular risk in women: focus on hypertension. Canadian Journal of Cardiology 2014; 30 (5): 553-559.
4. Appelman Y, Van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis 2015; 241 (1): 211-218.
5. Wenger NK, Ferdinand KC, Bairey Merz CN, Walsh MN, Gulati M et al. Women, hypertension, and the systolic blood pressure intervention trial. The American Journal of Medicine 2016; 129 (10): 1030-1036.
6. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR et al. Heart disease and stroke statistics - 2018 update: a report from the American Heart Association. Circulation 2018; 137 (12): e67-e492.
7. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal 2008; 29 (21): 2669- 2680.
8. Merz AA, Cheng S. Sex differences in cardiovascular ageing. Heart 2016; 102 (11): 825-831.
9. Wenger NK, Arnold A, Bairey Merz CN, Cooper-DeHoff RM, Ferdinand KC et al. Hypertension across a woman’s life cycle. Journal of the American College of Cardiology 2018; 71 (16): 1797-1813.
10. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology 2018; 71 (19): e127-248.
11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018; 39 (33): 3021-3104.
12. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circulation Cardiovascular Quality and Outcomes 2010; 3 (2): 135-142.
13. Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY et al. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. Journal of the American College of Cardiology 2018; 71 (18): 1960-1969.
14. Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspectives in Clinical Research 2015; 6 (4): 184-189.
15. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK et al. A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine 2015; 373 (22): 2103-2116.
16. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK et al. The design and rationale of a multi-center clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials 2014; 11 (5): 532-546.
17. Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management 2009; 5: 757-765.
18. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in Diabetes - 2018. Diabetes Care 2018; 41 (Suppl 1): S13-S27.
19. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378 (9799): 1297-1305.
20. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316 (7137): 1043-1047.
21. O’Malley SS, Wu R, Mayne ST, Jatlow PI. Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine and Tobacco Research 2014; 16 (8): 1145-1149.
22. Basu S, Sussman JB, Rigdon J, Steimle L, Denton BT et al. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLoS Medicine 2017; 14 (10): e100241.
23. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392 (10152): 1036-1046.
24. The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. New England Journal of Medicine 2018; 379 (16): 1529-1539.
25. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. New England Journal of Medicine 2018; 379 (16): 1509-1518.
26. Mikkola TS, Gissler M, Merikukka M, Tuomikoski P, Ylikorkala O. Sex differences in age-related cardiovascular mortality. PLOS One 2013; 8 (5): e63347.
27. Pirkle JL, Freedman BI. Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. Minerva Urologica e Nefrologica 2013; 65 (1): 37-50.
28. Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Internal Medicine 2017; 177 (10): 1498-1505.
29. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T et al. Effects of intensive BP control in CKD. Journal of the American Society of Nephrology 2017; 28 (9): 2812-2823.
30. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB et al. Effects of intensive blood pressure treatment on acute kidney injury events in the Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Kidney Diseases 2018; 71 (3): 352-361.
31. Foraker RE, Abdel-Rasoul M, Kuller LH, Jackson RD, Van Horn L et al. Cardiovascular health and incident cardiovascular disease and cancer: The Women’s Health Initiative. American Journal of Preventive Medicine 2016; 50 (2): 236-240.
32. Lindhorst J, Alexander N, Blignaut J, Rayner B. Differences in hypertension between blacks and whites: an overview. Cardiovascular Journal of Africa 2007; 18 (4): 241-247.
33. Fulgoni VL 3rd, Agarwal S, Spence L, Samuel P. Sodium intake in US ethnic subgroups and potential impact of a new sodium reduction technology: NHANES Dietary Modeling. Nutrition Journal 2014; 13 (1): 1-9.
34. Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD et al. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM Programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). Journal of the American College of Cardiology 2013; 62 (20): 1845-1854.
35. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. The Archives of Internal Medicine 2007; 167 (16): 1752-1759.
36. Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Drugs and Aging 1999; 14 (2): 141-152.
37. Seravalle G, Grassi G. Obesity and hypertension. Pharmacological Research 2017; 122: 1-7.
38. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI et al. Obesityrelated hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. The Journal of Clinical Hypertension 2013; 15 (1): 14-33.
39. Halm MA. Arm circumference, shape, and length: how interplaying variables affect blood pressure measurement in obese persons. American Journal of Critical Care 2014; 23 (2): 166-170.
40. Frohlich ED, Susic D. Mechanisms underlying obesity associated with systemic and renal hemodynamics in essential hypertension. Current Hypertension Reports 2008; 10: 151-155.
41. Stookey JD, Barclay D, Arieff A, Popkin BM. The altered fluid distribution in obesity may reflect plasma hypertonicity. European Journal of Clinical Nutrition 2007; 61: 190-199.
42. Echouffo-Tcheugui JB, Niiranen TJ, Mccabe EL, Jain M, Vasan RS et al. Lifetime prevalence and prognosis of prediabetes without progression to diabetes. Diabetes Care 2018; 41: e117-e118.
43. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology 2019; 73 (24): e285-e350.
44. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clinics in Geriatric Medicine 2012; 28 (2): 173-186.
45. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C et al. Effect of estrogen plus progestin on stroke in postmenopausal women: a randomized trial. JAMA 2003; 289 (20): 2673-2684.
46 . Shimbo D, Wang L, Lamonte MJ, Allison M, Wellenius GA et al. The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women’s Health Initiative randomized controlled trials. Journal of Hypertension 2014; 32 (10): 2071- 2081.
47. Ferrucci A, Pignatelli G, Sciarretta S, Tocci G. Hypertension in premenopausal women: is there any difference? High Blood Pressure and Cardiovascular Prevention 2014; 21 (3): 195-199.